L Proctor1, M Pradhan2, S Leung3, A Cheng3, C H Lee4, R A Soslow5, C B Gilks6, A Talhouk7, J M McAlpine1, H E Danielsen8, L N Hoang9. 1. Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, British Columbia, Canada. 2. Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway. 3. Genetic Pathology Evaluation Center and Vancouver General Hospital, Vancouver, British Columbia, Canada. 4. Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 6. Genetic Pathology Evaluation Center and Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 7. Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 8. Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom. 9. Genetic Pathology Evaluation Center and Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: Lien.Hoang@vch.ca.
Abstract
OBJECTIVE: We sought to determine whether DNA ploidy correlates with the four molecular subgroups of endometrial carcinoma (EC) as determined using ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). METHODS: 90 cases of EC previously characterized by clinicopathological parameters, outcomes, and ProMisE molecular subgroup (POLE EDM, MMR-D, p53 wt or p53 abn) were assessed for DNA ploidy using image cytometry. Associations of ploidy with traditional clinicopathological parameters were also tested. RESULTS: Abnormal DNA ploidy status differed amongst the ProMisE groups (p<0.001) and was found in 80.9% (17/21) of p53 abn, 37.0% (10/27) of p53 wt, 28.6% (4/14) of POLE EDM and 14.3% (4/28) of MMR-D. Abnormal DNA content was significantly associated with lower BMI (p=0.034) and grade 3 tumors (p=0.001). In the entire cohort, abnormal DNA content was significantly associated with worse progression free survival (p=0.0094) but not disease specific survival (p=0.249) or overall survival (p=0.187). When examining ploidy within each of the ProMisE groups, abnormal DNA content correlated with worse overall survival (p=0.041) and progression free survival (p=0.011) in the MMR-D group. No statistically significant relationship was seen in the remaining 3 groups. CONCLUSION: Abnormal DNA ploidy status did correlate with the molecular subgroups of EC; abnormal DNA content was seen in the large majority of p53 abn cases. Abnormal ploidy however was also seen in smaller numbers in the p53 wt, POLE EDM and MMR-D groups; therefore abnormal DNA content was not a specific marker for any one molecular group. The addition of ploidy to the ProMisE molecular categories conferred additional prognostic value within the MMR-D group, which merits further study.
OBJECTIVE: We sought to determine whether DNA ploidy correlates with the four molecular subgroups of endometrial carcinoma (EC) as determined using ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). METHODS: 90 cases of EC previously characterized by clinicopathological parameters, outcomes, and ProMisE molecular subgroup (POLE EDM, MMR-D, p53 wt or p53 abn) were assessed for DNA ploidy using image cytometry. Associations of ploidy with traditional clinicopathological parameters were also tested. RESULTS: Abnormal DNA ploidy status differed amongst the ProMisE groups (p<0.001) and was found in 80.9% (17/21) of p53 abn, 37.0% (10/27) of p53 wt, 28.6% (4/14) of POLE EDM and 14.3% (4/28) of MMR-D. Abnormal DNA content was significantly associated with lower BMI (p=0.034) and grade 3 tumors (p=0.001). In the entire cohort, abnormal DNA content was significantly associated with worse progression free survival (p=0.0094) but not disease specific survival (p=0.249) or overall survival (p=0.187). When examining ploidy within each of the ProMisE groups, abnormal DNA content correlated with worse overall survival (p=0.041) and progression free survival (p=0.011) in the MMR-D group. No statistically significant relationship was seen in the remaining 3 groups. CONCLUSION: Abnormal DNA ploidy status did correlate with the molecular subgroups of EC; abnormal DNA content was seen in the large majority of p53 abn cases. Abnormal ploidy however was also seen in smaller numbers in the p53 wt, POLE EDM and MMR-D groups; therefore abnormal DNA content was not a specific marker for any one molecular group. The addition of ploidy to the ProMisE molecular categories conferred additional prognostic value within the MMR-D group, which merits further study.
Authors: Tjalling Bosse; Remi A Nout; Jessica N McAlpine; Melissa K McConechy; Heidi Britton; Yaser R Hussein; Carlene Gonzalez; Raji Ganesan; Jane C Steele; Beth T Harrison; Esther Oliva; August Vidal; Xavier Matias-Guiu; Nadeem R Abu-Rustum; Douglas A Levine; C Blake Gilks; Robert A Soslow Journal: Am J Surg Pathol Date: 2018-05 Impact factor: 6.394
Authors: Vivian S Park; Meijuan J S Sun; Wesley D Frey; Leonard G Williams; Karl P Hodel; Juliet D Strauss; Sydney J Wellens; James G Jackson; Zachary F Pursell Journal: NAR Cancer Date: 2022-03-03
Authors: Hao-Dong Li; Changzheng Lu; He Zhang; Qing Hu; Junqiu Zhang; Ileana C Cuevas; Subhransu S Sahoo; Mitzi Aguilar; Elizabeth G Maurais; Shanrong Zhang; Xiaojing Wang; Esra A Akbay; Guo-Min Li; Bo Li; Prasad Koduru; Peter Ly; Yang-Xin Fu; Diego H Castrillon Journal: JCI Insight Date: 2020-07-23
Authors: Sara Imboden; Denis Nastic; Mehran Ghaderi; Filippa Rydberg; Tilman T Rau; Michael D Mueller; Elisabeth Epstein; Joseph W Carlson Journal: PLoS One Date: 2019-03-27 Impact factor: 3.240
Authors: Yun Du; Xiao Guo; Rui Wang; Yang Ma; Yan Zhang; Ying Liu; Lvli Dong; Juan Wu; Xiaokun Ji; Heng Wang Journal: J Cancer Date: 2020-02-06 Impact factor: 4.207